Evidence map›Paper›PMID 34297271›Full record

ArticleJournal of natural medicines2022

Bie Jia Jian pill enhances the amelioration of bone mesenchymal stem cells on hepatocellular carcinoma progression.

Huang Jingjing, Huang Hongna, Wang Xiaojiao, Guo Yan, Zhong Yuexue, Hu Yueqiang

Open access · hybridAbstract read
In one paragraph

Article in Journal of natural medicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Huang Jingjing *Department of Spleen, Stomach and Liver Diseases, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, P.R. China.
Huang Hongna *Teaching and Research Office of Internal Medicine of Traditional Chinese Medicine, The First Affiliated Hospital of Guangxi University of Chinese Medicine, No. 89-9, Dongge Road, Qingxiu District, Nanning, 530200, Guangxi, P.R. China.
Wang XiaojiaoThe First Clinical Medical College of Guangxi University of Chinese Medicine, Nanning, P.R. China.
Guo YanThe First Clinical Medical College of Guangxi University of Chinese Medicine, Nanning, P.R. China.
Zhong YuexueThe First Clinical Medical College of Guangxi University of Chinese Medicine, Nanning, P.R. China.
Hu YueqiangTeaching and Research Office of Internal Medicine of Traditional Chinese Medicine, The First Affiliated Hospital of Guangxi University of Chinese Medicine, No. 89-9, Dongge Road, Qingxiu District, Nanning, 530200, Guangxi, P.R. China. huyq@gxtcmu.edu.cn.ORCID http://orcid.org/0000-0001-9636-0315
Guangxi University · CNThe First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine · CN

Funding

National Natural Science Foundation of China 81403382National Natural Science Foundation of China 81760845Promotive Research Fund for Excellent Young and Middle-aged teachers in Colleges and Universities of Guangxi Province 2019KY0313
6 · The paper itself

Abstract

backgroundThe therapeutic efficiency of Traditional Chinese Medicine (TCM) in suppressing the recurrence and metastasis of hepatocellular carcinoma (HCC) has been well proved.

objectiveThe aim of this study is to investigate the role of Bie Jia Jian pill (BJJP) combined with bone mesenchymal stem cells (BMSCs) in HCC progression.

methodsFlow cytometry was used to identify BMSCs isolated from BALB/c mice. The expressions of biomarkers and apoptosis rate of cancer stem cells (CSCs) enriched from Huh7 cells were also measured. The osteogenic differentiation and adipogenic differentiation ability of isolated BMSCs was determined by oil red O staining and Alizarin Red Staining. CSCs were used to establish the orthotopic HCC model. Histological changes in the liver tissues were examined by hematoxylin-eosin (H&E) staining and Van Gieson (VG) staining. The cell apoptotic rate in the cancer tissues was detected by TUNEL staining. The cell proliferation antigen Ki67 in the cancer tissues were detected by immunofluorescence assay and PCR, respectively. The levels of CSCs cellular surface markers (CD24, CD133 and EpCAM) and Wnt/β-catenin signal pathway related proteins were detected by PCR and western blot.

resultsTreatment of BJJP or BMSCs both improved the morphology induced by HCC and suppressed the differentiation ability of CSCs, as evidenced by down-regulated expressions of CD24, CD133, EpCAM and Ki67. The protective effect of BJJP or BMSCs in cancer tissues can be enhanced by the combination of BJJP and BMSCs. In addition to that, BJJP or BMSCs alone was found to increase the expression of miR-140 and promote cell apoptosis in CSCs, while down-regulation of miR-140 partially reversed the protective effect of BMSCs or BJJP + BMSCs on cancer tissues. BJJP + BMSCs treatment together also can down-regulate the expressions of Wnt3a and β-catenin.

conclusionsThese results proved the inhibitory role of BJJP + BMSCs in HCC development through regulating miR-140 and Wnt/β-catenin signal pathway.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsMesenchymal Stem CellsMicroRNAsAnimalsbeta CateninCell DifferentiationCells, CulturedDrugs, Chinese HerbalMiceOsteogenesisWnt Signaling Pathwaybeta Cateninbie jia jianDrugs, Chinese HerbalMicroRNAsBie Jia Jian pillBone mesenchymal stem cellsCancer stem cellsHepatocellular carcinomaMicroRNA 140

Identifiers

PMID34297271
PMCPMC8732910
OpenAlexW3185469597

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.